# Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

> **NCT04813627** · — · ACTIVE_NOT_RECRUITING · sponsor: **BioNTech SE** · enrollment: 2200 (estimated)

## Conditions studied

- Colorectal Cancer Stage II
- Colorectal Cancer Stage III

## Interventions

- **PROCEDURE:** Regular blood sample collection for ctDNA assessment

## Key facts

- **NCT ID:** NCT04813627
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-02
- **Primary completion:** 2025-04-23
- **Final completion:** 2026-04
- **Target enrollment:** 2200 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813627, "Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04813627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*